Navigation Links
The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
Date:6/8/2009

NEW ORLEANS, June 8 /PRNewswire/ -- Today, The Lancet published online the results of the Novo Nordisk (NVO) LEAD(TM) 6 study, a direct comparison between two products in a new class of diabetes treatments, the GLP-1 receptor agonists. Results show that patients treated with liraglutide had a statistically greater drop in A1C than those who received exenatide.

The study compared liraglutide, a human GLP-1 analog, which is under investigation as a treatment for type 2 diabetes, to exenatide, the currently marketed GLP-1 receptor agonist.

"Because of the differences in how the body absorbs and eliminates these two compounds, we were very interested to see if there were clinically meaningful differences in the effect in people with diabetes," said Dr. John Buse, chief of endocrinology and director of the Diabetes Care Center at the University of North Carolina School of Medicine, and one of the principal investigators in the study. "The clinical benefits that liraglutide provides -- from greater glucose lowering to weight loss to better tolerability and improvements in beta-cell function -- represent a clinically meaningful treatment advance for patients with type 2 diabetes."

LEAD(TM) 6 was a randomized, open-label study comparing the efficacy and safety of liraglutide 1.8 milligrams, once a day, to exenatide 10 micrograms, twice a day.

Treatment with liraglutide led to a statistically significantly greater drop in A1C of 1.12% compared to 0.79% in the exenatide group, and liraglutide was also significantly better than exenatide at lowering fasting plasma glucose (-1.61 mmol/L vs -0.60 mmol/L) in this typical type 2 diabetes population. The study comprised 464 patients who were not reaching recommended blood sugar targets on either the maximally tolerated doses of metformin, sulphonylurea, or both, which are standard oral antidiabetic medications currently availabl
'/>"/>

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
3. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
6. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
7. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
8. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
9. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
10. SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa
11. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food and ... for the prevention of serogroup B meningococcal disease ... Pfizer,s vaccine Trumenba®, which received FDA approval in October, ... devastating disease. "I have heard over ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015 Research and Markets ... of the "Urinary Catheters Market (Indwelling or Foley ... - Global Industry Analysis, Size, Share, Growth, Trends and ... , At present, the global market ...
(Date:1/23/2015)... Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... DCVax® personalized immune therapies for operable and inoperable solid tumor ... present at the 7 th Annual Phacilitate Immunotherapy Forum ... Bio,s presentation at Phacilitate will take place on January 26 ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... N.J., Nov. 15, 2011 "Blueprint to Quit" ... resources for smokers interested in quitting, available exclusively ... to online behavioral support resources on QuitNet.com – ... materials and self-assessment tools – and nicotine replacement ...
... 2011 Innocoll Inc. announced it has entered into a ... for CollaGUARD surgical adhesion barrier for the prevention of postoperative ... Michael Myers, President and CEO stated, "We are pleased to ... CollaGUARD and we look forward to the successful launch of ...
Cached Medicine Technology:New "Blueprint to Quit" Comprehensive Smoking Cessation Program Available for Smokers 2New "Blueprint to Quit" Comprehensive Smoking Cessation Program Available for Smokers 3New "Blueprint to Quit" Comprehensive Smoking Cessation Program Available for Smokers 4Innocoll Enters Partnership with Merus Labs in Canada for the Distribution of CollaGUARD 2Innocoll Enters Partnership with Merus Labs in Canada for the Distribution of CollaGUARD 3
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to ... Pharmacy Services at North Carolina State’s College of Veterinary ... Beal Award for Distinguished Volunteer Service—the organization’s highest award. ... contributions of volunteer experts to direct its work to ...
(Date:1/22/2015)... 2015 The City of West Hollywood hosted a ... commemorate the 42nd anniversary of the Supreme Court decision Roe v. ... 42 years since the Roe vs. Wade decision and the fight ... as ever,” said City of West Hollywood Councilmember Abbe Land. “We ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ has ... (PPHA). The PPHA's passion for others' well-being and shared ... treated for obstructive sleep apnea (OSA) has propelled them into ... the valley. The most recent plans for an event will ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Public Can Directly Interact with Harvard Medical Doctors Via ... First Live Chat with Dr. Julie Silver, Harvard Medical ... 8 p.m. EDT, BOSTON, Oct. 28 Beginning ... top Harvard Medical doctor -without,leaving your laptop. Gather ...
... As October, Breast Cancer Awareness,Month, draws to ... Georgia (BCBSGa),understands that it is truly a year-round ... breast cancer care and awareness for its members.,The ... with breast,cancer and their physicians, has helped more ...
... on the Proposed Transfer of Listing of its ... H Shares from GEM to ... Shandong Luoxin Pharmacy,Stock Co., Ltd. (HKEx: 8058), announced its third ... a strong growth in turnover,and profit attributable to shareholders., ...
... Patients Lose 35% More Weight and Have Better Quality ... Surgery Itself, GAINESVILLE, Fla., Oct. 28 Those ... surgery lost 35,percent more weight the first year and ... according to new patient and bariatric surgeon surveys,conducted by ...
... health costs and medical crises fuel many foreclosures, bankruptcies ... and Deborah Krinsky of Magalia, Calif., have seen their ... And their health-care costs have put them in a ... and potential heart problems, Deborah,s connective tissue disorder and ...
... MPX Workstation and International Business Drive Top-Line Growth; ... Quarter of Profitability, WESTFORD, Mass., Oct. 28 ... manufacturer of a broad array of,light-based aesthetic treatment systems, ... ended September 30, 2008., Third-Quarter 2008 Financial Results, ...
Cached Medicine News:Health News:Gather and Harvard Health Publications Launch New Programs to Bring Harvard Medical School Doctors' Expertise Online 2Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 2Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 3Health News:Luoxin Announces 2008 Third Quarterly Results; Profit Attributable to Shareholders Surged 62.9% to Approximately RMB 138,141,000 2Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 2Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 3Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 4Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 5Health News:Medical Debt Sending Many Over Financial Brink 2Health News:Medical Debt Sending Many Over Financial Brink 3Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 2Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 3Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 4Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 5Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 6Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 7Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 8Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 9Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 10Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 11
... AvantGard Low Binding 20l Barrier Tips. Low ... DNA and proteins bound to the tip. Most ... which means the focus is on liquid not ... focuses on low binding which reduces the binding ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
... Aerosol Resistant Tips offer a safe alternative ... are designed for applications such as PCR(a), ... addition, ART Tips are excellent for tissue ... studies. ART Tips prevent aerosol contaminants and ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
Medicine Products: